Current Edition

The Role of Biomarkers in Parkinson’s Disease

In Parkinson’s disease, PD, the examination of post-mortem brain
tissue has led to the identification of relevant molecular pathways
and genes that have allowed for targeted therapies, development
of animal models, and new drug delivery systems. These targeted
strategies have identified many biomarker candidates that are
being actively evaluated for their potential as different types of PD
biomarkers. The following article, written by Tomislav Babic, MD,
PhD, Vice President of Medical and Scientific Affairs/Neuroscience
Franchise at Worldwide Clinical Trials Inc., will discuss these
biomarkers in depth.